Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Beam Therapeutics excels in base editing therapies, poised for growth

Beam Therapeutics showcased strong performance in trials and technology development, positioning itself as a leader in base editing therapies.
While facing challenges in clinical translation and regulatory landscapes, Beam's focus on innovative solutions presents growth opportunities in gene editing.
Overall, Beam's financial strength, promising data, and strategic vision offer a solid foundation for future success in the biotech industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Pfizer

Pfizer has completely transformed its fortunes with its discovery and development of Comirnaty, the COVID vaccine, and more recently, COVID antiviral Paxlovid. Despite partnering with BioNTech on Comirnaty, Pfizer appears to be exploring its options and working with other partners, including Codex DNA, and now Beam Therapeutics.

Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy

A new partnership with Pfizer will inject a lot of cash into Beam Therapeutics' coffers.

Is Beam Therapeutics a Good Stock to Buy Now?

Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.

Pfizer (PFE) Partners Beam Therapeutics for Rare Disease Drugs

The string of new deals announced Monday include a potential deal with gene editing specialist Beam Therapeutics, including a $300 million upfront payment.

Pfizer Bets Big On mRNA: New Deals Include $1.3 Billion Collaboration With Beam

Shares of Pfizer Inc. PFE, +1.60% gained 0.2% in premarket trading on Monday after the company announced a deal with Beam Therapeutics Inc. BEAM, -0.78% worth up to $1.3 billion. Beam's stock was up 4.9% before the market opened.

Pfizer announces deal worth up to $1.3 billion with Beam; Beam's stock is up 4.9%

Pfizer Inc (NYSE: PFE) and Beam Therapeutics Inc (NASDAQ: BEAM) have announced an exclusive four-year research collaboration focused on in vivo base editing programs. The collaboration may be extended up to one additional year.

Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs

Drugmaker Pfizer will collaborate with gene-editing specialist Beam Therapeutics in a deal worth as much as $1.35 billion to develop therapies for rare genetic diseases.

Pfizer joins Beam Therapeutics to develop rare disease therapies

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. The base editing programs to be evaluated as part of the collaboration will leverage Beam's proprietary i

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

Amgen

Vir Biotechnology

These stocks are poised for a strong year.

My 3 Top Biotech Stock Picks for 2022

First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Verve Therapeutics

These CRISPR stocks could be big winners for patient investors.

The Best CRISPR Companies to Invest In

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 2:15 p.m. ET.

Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick

BEAM's novel CRISPR technology gives it a niche in a crowded and volatile market alongside other CRISPR companies trading at high valuations. While the 'standard' CRISPR-cas9 approach cuts double-stranded DNA and to insert genetic sequences, base editing erases a point mutation and replaces with a new letter.

Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity

CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today shared a three-stage, long-term development strategy for its base editing approach to treat sickle cell disease (SCD). The plan, and supportive data, are being presented during a Scientific Program Session oral presentation and two poster sessions at the 63rd American Society for Hematology (ASH) Annual Meeting & Exposition.

Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH

Adaptimmune Therapeutics

Affimed

Aurinia Pharmaceuticals

Axsome Therapeutics

BridgeBio Pharma Inc

BioCryst Pharmaceuticals

Amicus Therapeutics

SPDR S&P Biotech ETF

These eight stocks could rebound nicely over the next year and beyond.

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022

Gilead Sciences

Vertex Pharmaceuticals

Two big biotechs and one smaller one that could be winners over the long term.

Got $1,000? Check Out These 3 Top Biotech Stocks

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Jefferies 2021 Virtual London Healthcare Conference, being held November 16-19, 2021. The fireside chat will be available to registered participants on-demand between 8:00 a.m. GMT on November 18, 2021, and 5:00 p.m. GMT on November 19, 2021.

Beam Therapeutics to Participate in the Jefferies 2021 Virtual London Healthcare Conference

Can this high-flying gene-editing stock keep on climbing for new investors?

Cathie Wood's Buying Beam Therapeutics -- Should You?

The biotech will use its one-time "base-editing" genetic treatment to alleviate sickle-cell disease.

Beam Gets FDA Nod for First Gene-Editing Trial

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Maraganore, Ph.D., founding chief executive officer and director of Alnylam Pharmaceuticals, has joined the company's board of directors.

Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors

BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease

Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results

Preclinical Data Demonstrates that BEAM-102 Makassar Base Editing Converts Sickle Hemoglobin to Functional Hemoglobin for Potential Treatment of Sickle Cell Disease

Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting

Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Beam Therapeutics Inc. (BEAM) to Report a Decline in Earnings: What to Look Out for

Teladoc

These stocks are risky, though, and ideally suited for aggressive investors.

News for Beam Therapeutics Stock (BEAM)